Providing New Healthcare Options Through Perinatal-Derived Cells
First written in FY2021. 10 of 12 entries say "Restated". Latest entry: 2026-10-30.
No other company in this theme has enough history to compare yet.
- FY2026RestatedAnnual report
「Our group operates a cell banking business based on cells derived from perinatal tissues, including umbilical cords and cord blood, for regenerative medicine and cell therapy, leveraging our strong network with obstetrics and gynecology facilities under the corporate slogan “New healthcare options for new life.”」
We continue to pursue our basic policy of providing new healthcare options through regenerative medicine and cell therapy, based on our perinatal tissue-derived cell banking business. - FY2026-H1RestatedAnnual report
「Based on this business platform, we aim to achieve global and sustainable growth and contribute to society through business development and investment in related fields, including regenerative medicine and femtech.」
We have reaffirmed our policy of pursuing global and sustainable growth through business development and investment in regenerative medicine, femtech and other related fields. - FY2026-H1RestatedAnnual report
「Our group uses “New healthcare options for new life” as its corporate slogan and leverages its strong network with obstetrics and gynecology facilities to operate a cell banking business involving perinatal tissue-derived cells, including “umbilical cord” and “cord blood,” for regenerative medicine and cell therapy, as well as developing new treatments using these cells. Based on this business platform, we aim to achieve global and sustainable growth and contribute to society through business development and investment in related fields, including regenerative medicine and femtech.」
We continue to pursue our policy of achieving growth and contributing to society through perinatal tissue-derived cell banking, treatment development, and business development and investment in regenerative medicine, femtech and other fields. - FY2025RestatedAnnual report
「We use “New healthcare options for new life” as our corporate slogan and leverage our strong network with obstetrics and gynecology facilities to operate a cell banking business involving perinatal tissue-derived cells, including “umbilical cord” and “cord blood,” for regenerative medicine and cell therapy, as well as developing new treatments and products using these cells.」
We continue to pursue our basic policy of contributing to society and achieving sustainable growth through business development and investment in related fields, based on our perinatal tissue-derived cell banking business and the development of treatments and products. - FY2024-Q3RestatedAnnual report
「StemCell Institute uses “New healthcare options for new life” as its corporate slogan and leverages the strong network it has built with obstetrics and gynecology facilities across Japan to operate a cell banking business involving perinatal tissue-derived cells, including “cord blood” and “umbilical cord,” for regenerative medicine and cell therapy, as well as developing new treatments and regenerative medicine products using these cells. Based on this business platform, we aim to achieve sustainable growth and contribute to society through business development and investment in the femtech field, including regenerative medicine, fertility treatment, childbirth and childcare.」
We continue to pursue our basic policy of providing new healthcare options through perinatal tissue-derived cell banking, the development of treatments and regenerative medicine products, and business development and investment in the femtech field. - FY2024-Q2RestatedAnnual report
「StemCell Institute uses “New healthcare options for new life” as its corporate slogan and leverages the strong network it has built with obstetrics and gynecology facilities across Japan to operate a cell banking business involving perinatal tissue-derived cells, including “cord blood” and “umbilical cord,” for regenerative medicine and cell therapy, as well as developing new treatments and regenerative medicine products using these cells.」
We continue to pursue our basic policy of providing new healthcare options through a perinatal tissue-derived cell banking business and the development of treatments and regenerative medicine products using these cells. - FY2024-Q1RestatedAnnual report
「StemCell Institute uses “New healthcare options for new life” as its corporate slogan and operates a cell banking business involving perinatal tissue-derived cells, including “cord blood” and “umbilical cord,” for regenerative medicine and cell therapy, as well as developing new treatments and regenerative medicine products using these cells.」
We continue to pursue our policy of providing new healthcare options through a perinatal tissue-derived cell banking business and the development of treatments and regenerative medicine products using these cells. - FY2023RestatedAnnual report
「To realize our corporate slogan, “New healthcare options for new life,” we will continue to accumulate expertise, develop technologies and improve services in our cell banking business, centered on stem cells derived from perinatal tissues.」
We continue to pursue our basic policy of providing new healthcare options through a cell banking business centered on stem cells derived from perinatal tissues. - FY2022RestatedAnnual report
「To realize our corporate slogan, “New healthcare options for new life,” we will continue to accumulate expertise, develop technologies and improve services in our cell banking business, centered on stem cells derived from perinatal tissues.」
We continue to pursue our basic policy of providing new healthcare options through a cell banking business centered on stem cells derived from perinatal tissues. - FY2021First statedAnnual report
「To realize our corporate slogan, “New healthcare options for new life,” we will continue to accumulate expertise, develop technologies and improve services in our cell banking business, centered on stem cells derived from perinatal tissues.」
Our basic policy is to contribute to advances in healthcare and society through our cell banking business for patients suffering from conditions for which no treatment is available.